Literature DB >> 17966434

Cell-mediated defense against Yersinia pestis infection.

Stephen T Smiley1.   

Abstract

Yersinia pestis (Yp)--one of the world's most deadly human pathogens--is the gram-negative bacterium that causes pneumonic plague. Virulent antibiotic-resistant Yp strains exist and Cold War scientists devised means to effectively aerosolize Yp. These facts raise grave concern that Yp will be exploited as a bioweapon. To counter that possibility, it is essential that we develop a safe and effective pneumonic plague vaccine. Recent studies suggest that the leading vaccine candidate, which primarily stimulates antibody-mediated humoral immunity, may not suffice. T cell-dependent cellular immunity comprises a second means by which vaccines prime long-lived protection against virulent bacterial pathogens. However, a plasmid carried by virulent Yp encodes factors that dampen inflammation and debilitate phagocytes, thereby compromising cellular defense mechanisms. As such, plague vaccine researchers have devoted relatively little attention to cellular immunity. Here we review our recent work demonstrating that the passive transfer of primed T cells can suffice to protect mice against lethal intranasal Yp infection, a model of pneumonic plague. We also demonstrate that key elements of cellular immunity even play critical roles during antibody-mediated defense against plague. We conclude that next-generation plague vaccines should strive to prime both cellular and humoral immunity.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17966434     DOI: 10.1007/978-0-387-72124-8_35

Source DB:  PubMed          Journal:  Adv Exp Med Biol        ISSN: 0065-2598            Impact factor:   2.622


  18 in total

1.  Flagellin adjuvanted F1/V subunit plague vaccine induces T cell and functional antibody responses with unique gene signatures.

Authors:  Fahreta Hamzabegovic; Johannes B Goll; William F Hooper; Sharon Frey; Casey E Gelber; Getahun Abate
Journal:  NPJ Vaccines       Date:  2020-01-23       Impact factor: 7.344

2.  Intranasal delivery of a protein subunit vaccine using a Tobacco Mosaic Virus platform protects against pneumonic plague.

Authors:  Paul M Arnaboldi; Mariya Sambir; Christina D'Arco; Lauren A Peters; Jos F M L Seegers; Lloyd Mayer; Alison A McCormick; Raymond J Dattwyler
Journal:  Vaccine       Date:  2016-10-13       Impact factor: 3.641

3.  High-throughput, signature-tagged mutagenic approach to identify novel virulence factors of Yersinia pestis CO92 in a mouse model of infection.

Authors:  Duraisamy Ponnusamy; Eric C Fitts; Jian Sha; Tatiana E Erova; Elena V Kozlova; Michelle L Kirtley; Bethany L Tiner; Jourdan A Andersson; Ashok K Chopra
Journal:  Infect Immun       Date:  2015-03-09       Impact factor: 3.441

4.  Involvement of CD8+ T cell-mediated immune responses in LcrV DNA vaccine induced protection against lethal Yersinia pestis challenge.

Authors:  Shixia Wang; Jon D Goguen; Fusheng Li; Shan Lu
Journal:  Vaccine       Date:  2011-01-01       Impact factor: 3.641

5.  Comparative Analyses of Transcriptional Profiles in Mouse Organs Using a Pneumonic Plague Model after Infection with Wild-Type Yersinia pestis CO92 and Its Braun Lipoprotein Mutant.

Authors:  Cristi L Galindo; Scott T Moen; Elena V Kozlova; Jian Sha; Harold R Garner; Stacy L Agar; Ashok K Chopra
Journal:  Comp Funct Genomics       Date:  2010-01-20

6.  SAR studies for a new class of antibacterial NAD biosynthesis inhibitors.

Authors:  Whitney Beysselance Moro; Zhengrong Yang; Tasha A Kane; Qingxian Zhou; Steve Harville; Christie G Brouillette; Wayne J Brouillette
Journal:  J Comb Chem       Date:  2009 Jul-Aug

7.  High-throughput identification of new protective antigens from a Yersinia pestis live vaccine by enzyme-linked immunospot assay.

Authors:  Bei Li; Lei Zhou; JingYu Guo; Xiaoyi Wang; Bin Ni; Yuehua Ke; Ziwen Zhu; Zhaobiao Guo; Ruifu Yang
Journal:  Infect Immun       Date:  2009-08-03       Impact factor: 3.441

Review 8.  Humoral and cell-mediated immunity to the intracellular pathogen Francisella tularensis.

Authors:  Girish S Kirimanjeswara; Sofia Olmos; Chandra S Bakshi; Dennis W Metzger
Journal:  Immunol Rev       Date:  2008-10       Impact factor: 12.988

9.  Virtual screening to identify lead inhibitors for bacterial NAD synthetase (NADs).

Authors:  Whitney Beysselance Moro; Zhengrong Yang; Tasha A Kane; Christie G Brouillette; Wayne J Brouillette
Journal:  Bioorg Med Chem Lett       Date:  2009-02-12       Impact factor: 2.823

10.  Use of bioengineered human commensal gut bacteria-derived microvesicles for mucosal plague vaccine delivery and immunization.

Authors:  A L Carvalho; A Miquel-Clopés; U Wegmann; E Jones; R Stentz; A Telatin; N J Walker; W A Butcher; P J Brown; S Holmes; M J Dennis; E D Williamson; S G P Funnell; M Stock; S R Carding
Journal:  Clin Exp Immunol       Date:  2019-04-15       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.